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Highlights	
•Survival from ovarian cancer depends on the morphological subtype of the tumour. 
•Type I epithelial tumours have much higher survival than type II tumours. 
•Survival from sex cord‐stromal tumours is the highest of the subtypes. 
Abstract	
Objective	
Ovarian cancer comprises several histological groups with widely differing levels of survival. We 
aimed to explore international variation in survival for each group to help interpret international 
differences in survival from all ovarian cancers combined. We also examined differences in stage-
specific survival. 
Methods	
The CONCORD programme is the largest population-based study of global trends in cancer 
survival, including data from 60 countries for 695,932 women (aged 15–99 years) diagnosed with 
ovarian cancer during 1995–2009. We defined six histological groups: type I epithelial, type II 
epithelial, germ cell, sex cord-stromal, other specific non-epithelial and non-specific morphology, 
and estimated age-standardised 5-year net survival for each country by histological group. We also 
analysed data from 67 cancer registries for 233,659 women diagnosed from 2001 to 2009, for 
whom information on stage at diagnosis was available. We estimated age-standardised 5-year net 
survival by stage at diagnosis (localised or advanced). 
Results	
Survival from type I epithelial ovarian tumours for women diagnosed during 2005–09 ranged from 
40 to 70%. Survival from type II epithelial tumours was much lower (20–45%). Survival from germ 
cell tumours was higher than that of type II epithelial tumours, but also varied widely between 
countries. Survival for sex-cord stromal tumours was higher than for the five other groups. Survival 
from localised tumours was much higher than for advanced disease (80% vs. 30%). 
Conclusions	
There is wide variation in survival between histological groups, and stage at diagnosis remains an 
important factor in ovarian cancer survival. International comparisons of ovarian cancer survival 
should incorporate histology. 
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1.	Introduction	
The CONCORD-2 study, a comprehensive study on cancer survival, showed wide variation in 5-
year net survival for ovarian cancer among over 779,000 women diagnosed in 61 countries [1]. 
Age-standardised survival from ovarian cancer for all histological groups combined was around 30–
40% in most countries from 1995 to 2009, but it varied widely between countries. Most 
international comparisons of ovarian cancer survival include all histological groups combined [1], 
[2], [3]. The different histological groups have unique molecular pathways and treatment, and 
survival also differs widely, especially for type I and type II epithelial tumours [4], [5], [6], [7]. We 
have examined patterns of survival for each distinct histological group in order to gain a better 
understanding of international differences in ovarian cancer survival. 
Type I epithelial tumours include low-grade serous, endometrioid, clear cell, mucinous and 
transitional cell (Brenner) carcinomas, while type II epithelial tumours include high-grade serous, 
undifferentiated carcinoma and malignant mixed mesodermal tumours (carcinosarcoma). Type II 
epithelial tumours account for approximately 70% of all malignant ovarian tumours, while only 
22% of ovarian tumours are type I epithelial. Type I epithelial tumours often present at an early 
stage and have better prognosis than Type II epithelial tumours, which typically present at an 
advanced stage [4]. Germ cell and sex cord-stromal tumours are rarer types of ovarian cancer, but 
they generally have much better prognosis than type II epithelial tumours. 
Stage at diagnosis also affects survival. Though most women are diagnosed at an advanced stage, 
stage-specific survival also differs widely between countries [2]. In a comparison of one-year net 
survival between six high-income countries, Denmark had the highest percentage of women with 
advanced disease and the second lowest survival for all stages combined [2]. Thus, the international 
variation in ovarian cancer survival may be partially explained by the distribution of stage at 
diagnosis. 
The CONCORD-2 study on the global surveillance of cancer survival has shown the extent to 
which ovarian cancer survival for all histological groups combined varies worldwide [1]. However, 
it remains unclear how much of the variation in ovarian cancer survival could be attributed to 
international variation in survival for each histological group. We aimed to examine survival from 
ovarian cancer by histological group and stage at diagnosis in order to improve understanding of 
international differences in ovarian cancer survival. 
2.	Material	and	methods	
The CONCORD-2 study was based on data for over 25.7 million patients diagnosed with one of 10 
cancers, contributed by 279 population-based cancer registries in 67 countries. The data included 
over 779,000 women diagnosed with ovarian cancer in 61 countries during the 15-year period of 
1995 to 2009 [1]. The CONCORD-2 protocol, ethical approvals and quality control procedures 
have been described [1]. 
We analysed data for women (aged 15–99 years) diagnosed during 1995–2009 with a cancer of the 
ovary, fallopian tube, uterine ligaments and adnexa, other specified and unspecified female genital 
organs, peritoneum and retroperitoneum (International Classification of Diseases for Oncology, 3rd 
edition (ICD-O-3) topography codes C56.9, C57.0-C57.4, C57.7-C57.9, C48.0-C48.2) [8]. Recent 
evidence suggests that high-grade serous carcinoma, the most common type of ovarian cancer, 
originates in the fallopian tube. Therefore, cancers of the fallopian tube were included in a broader 
definition of ovarian cancer [4]. Similarly, primary peritoneal malignancies are managed in the 
same way as advanced-stage epithelial ovarian cancer, and they are also included [4]. Tumours of 
the uterine ligaments and adnexa, other specified and unspecified female genital organs and 
retroperitoneum were included because of the close proximity of these sites to the ovaries, fallopian 
tubes and peritoneum. Follow-up until 31 December 2009 for vital status was available. Women 
diagnosed with ovarian cancer as a second or higher-order primary tumour are included in the 
analysis, in addition to those for whom ovarian cancer was their first cancer. Women whose cancer 
registration was from a death certificate or autopsy only were excluded, because their true survival 
time was unknown. 
In ICD-O-2, some borderline tumours were coded as malignant, or with a behaviour code of 3. The 
behaviour code changed, however, from malignant (behaviour code of 3) to not malignant or of 
borderline malignancy (behaviour code of 0 or 1) in ICD-O-3. Due to this change in coding, some 
women diagnosed with borderline tumours were included in the data submissions. ICD-O-3 
morphology codes were checked to detect borderline tumours that are now coded with behaviour 
codes of 0 or 1, and these tumours were then excluded from analysis because their inclusion would 
inflate survival estimates. 
We defined six histological groups based on ICD-O-3 codes, literature [9] and clinical advice: type 
I epithelial, type II epithelial, germ cell, sex cord-stromal, other specific non-epithelial and non-
specific morphology [Table 1]. Clear cell, endometrioid, mucinous, squamous and transitional cell 
(Brenner) carcinomas were classified as type I epithelial. Serous, mixed epithelial-stromal and 
undifferentiated or other classified epithelial carcinomas were grouped as type II epithelial. 
Tumours with a non-specific morphology code (8000–8004) were analysed separately. Survival for 
tumours with missing morphology (0.1% of cases) is not reported. We included in the analysis all 
microscopically verified tumours. We also included tumours that were reported as not 
microscopically verified but for which we had a specific ICD-O-3 morphology code (any valid 
ICD-O-3 code except 8000–8004). 
Table 1. Ovarian cancer histological groups and subtypesa. 
Histological 
group  Histological subtype  ICD‐O‐3 morphology code 
Type I epithelial 
Clear cell carcinoma  8005, 8310, 8443, 9110
Endometrioid 
carcinomab  8380, 8382–8383, 8560, 8570 
Mucinous carcinoma  8470–8471, 8480–8482, 8490
Squamous carcinoma  8051–8084
Transitional cell or 
Brenner carcinoma  8120–8131, 9000 
Type II epithelial 
Serous carcinomac  8050, 8441, 8450, 8460–8461
Mixed epithelial‐
stromal carcinoma  8313, 8323, 8381, 8930–8991, 9010–9030 
Undifferentiated or 
other epithelial 
8010–8015, 8020–8046, 8090–8110, 8140–8231, 8246–8300, 
8311–8312, 8314–8322, 8324–8325, 8336–8337, 8341–8375, 
8384–8440, 8452–8454, 8500–8551, 8561–8562, 8571–8589 
Germ cell  Germ cell 8240–8245, 8330–8335, 8340, 9060–9105, 9380–9523 
Sex cord‐
stromal  Sex cord‐stromal  8590–8671, 8810 
Other specific 
non‐epithelial 
Other specific non‐
epithelial  8680–8806, 8811–8921, 9040–9055, 9120–9373, 9530–9589 
Non‐specific  Non‐specific  8000–8004
a 
No information on grade was available, therefore all endometrioid tumours were classified 
as type I epithelial. 
b 
No information on grade was available, therefore all serous tumours were classified as type 
II epithelial. 
c 
Borderline tumours (ICD-O-3 codes: 8442, 8444, 8451, 8462, 8463, 8472, 8473) were 
excluded from the analysis of distribution of histological groups (see text). 
Information on stage at diagnosis was available only from 2001; therefore, the stage-specific 
analysis only includes patients diagnosed between 2001 and 2009. Stage at diagnosis was 
categorised into localised or advanced. Registries submitted stage data coded to one of several 
classifications: UICC Tumour-Node-Metastasis (TNM) staging system (7th edition), the Fédération 
Internationale de Gynécologie et d'Obstétrique (FIGO) system or SEER Summary Stage 2000. We 
received data on pathological and/or clinical T, N and M, as well as tumour size (in millimetres) 
and the number of positive lymph nodes. These data were used to create a final stage at diagnosis 
variable, prioritising pathological TNM information, supplemented with clinical TNM information 
where missing. Information on FIGO stage and SEER Summary Stage 2000 was used to 
supplement missing TNM information when both pathological and clinical TNM were missing, and 
if no data on tumour size or number of positive lymph nodes were available. TNM Stage I tumours 
are confined to the ovaries at diagnosis; and were defined as localised in these analyses. Stage II 
tumours are rare and have spread beyond the ovaries; these tumours were defined as advanced in 
these analyses. Stage III tumours have spread to regional lymph nodes and Stage IV tumours have 
metastasised to other organs. TNM Stage III and Stage IV tumours were defined as advanced. 
Where there was no information available on stage, we classified the tumours as of missing stage at 
diagnosis. 
We analysed survival by histological group in each country. We analysed survival by stage at 
diagnosis in each country, and where possible, for each registry, separately from the analysis by 
histological group. Only countries with at least 10 women for a given histological group for all 
years combined were included in the analysis for that histological group. For the stage-specific 
analysis, we included registries with at least 10 women available for analysis in each stage for any 
given time period. If more than 30% of tumours were missing stage at diagnosis for a given registry 
during 2004–2009, then that registry was excluded from the stage-specific analysis. If fewer than 10 
women were available for analysis in a given registry, then the registry was excluded from the 
analysis by stage at diagnosis. Registries for which net survival estimates were considered as less 
reliable in the main CONCORD-2 analysis [1] were also excluded. Country-level survival estimates 
were derived by pooling data for registries that were included in the registry-specific analysis by 
stage at diagnosis. We only included data from countries that were included in the analysis of 
specific histological groups in the analysis for non-specific morphology, given that there were at 
least 10 women with non-specific tumours available for all years combined. If fewer than 50 
women were available for survival analysis by histological group or stage at diagnosis in a given 
calendar period, the data for that country were merged. 
Net survival is defined as the probability of survival for cancer patients up to a given point in time 
after diagnosis (for example, 5 years) if death from cancer were to be the only cause of death. Net 
survival controls for the background mortality of competing causes of death in a population. We 
used the Pohar Perme estimator of net survival [10], which allows for the fact that competing risks 
of death increase with age. The Pohar Perme estimator was implemented using stns[11] in Stata 
version 14 [12]. 
Net survival is reported for each country and histological group, and separately for each registry and 
each stage at diagnosis. Survival by histological group was estimated for women diagnosed during 
1995–1999, 2000–2004 and 2005–2009. The cohort approach was used for women diagnosed 
during 1995–1999 and 2000–2004, because five or more years of follow-up were available for all 
patients, while a period approach was used for 2005–2009. Stage-specific survival was estimated 
with a cohort approach for 2001–03 and a complete approach was used for 2004–2009. 
Survival estimates for all ages combined were age-standardised, where possible, with the 
International Cancer Standard Survival (ICSS) weights [13]. Age at diagnosis was categorised into 
five age groups: 15–44, 45–54, 55–64, 65–74 and 75–99 years. If an age-specific estimate could not 
be produced, or fewer than 10 women were available for analysis in an age group, data for adjacent 
age groups were pooled and the re-estimated survival was used for both of the original age groups. 
If two or more age-specific estimates could not be produced, fewer than 10 women were available 
for analysis in two or more age groups, only the unstandardised estimate is reported. 
3.	Results	
Data for a total of 695,932 women were available for analysis of survival by histological group 
[Supplementary Fig. 1], including 98.3% with a specific morphology, 1.6% with non-specific 
morphology and 0.1% with missing morphology [Table 2]. Survival by histological group was 
estimated for all stages combined. Most women were diagnosed with Type II epithelial tumours. 
The mean age at diagnosis varied between histological group, ranging from 36 years for germ cell 
tumours to 66 years for tumours of non-specific morphology. 
Table 2. Worldwide distribution of histology and mean age at diagnosis, 1995–2009. 
Histological group  No. of patients % Mean age in years (SD)a
Type I epithelialb  152,970  22.0 58 (14)
Type II epithelialc  488,634  70.2 64 (14)
Germ cell  13,306  1.9 36 (18)
Sex cord‐stomal  11,430  1.6 54 (16)
Other specific non‐epithelial 17,619  2.5 61 (15)
Non‐specific tumours  11,282  1.6 66 (17)
Missing morphology  691  0.1 64 (16)
A Standard deviation. 
B No information on grade was available, therefore all endometrioid tumours were classified as type I 
epithelial. 
C No information on grade was available, therefore all serous tumours were classified as type II epithelial. 
Net survival for women diagnosed with type I epithelial tumours five years after diagnosis was 
fairly high, generally 50–60% [Fig. 1]. During 2005–2009, age-standardised 5-year survival for 
type I epithelial tumours varied widely, with the highest survival in Hong Kong (82.9%, 72.4–
93.4%) and the lowest in Argentina (30.8%, 16.3–45.2%) [Supplementary Table 1]. Age-
standardised survival from type I epithelial tumours also varied within each continent and over 
time. The between-country variation in survival was widest in Central and South America (from 
30.8%, 16.3–45.2% in Argentina to 77.1%, 64.7–89.6% in Colombia) for women diagnosed during 
2004–2009. Age-standardised net survival from type I tumours increased over time in all countries 
in Central and South America and North America for which data were available. In Asia, Europe, 
and Oceania, most countries saw an improvement in survival from type I tumours, but survival 
actually fell over time for some countries in these regions (from 65.5%, 59.0–72.1% to 60.8%, 
50.7–70.8% in Korea and from 60.3%, 49.8–70.7% to 56.9%, 42.6–71.3% in Turkey (Izmir)) 
Survival from type II epithelial tumours five years after diagnosis was lower than that of type I 
epithelial tumours, around only 20–45% [Fig. 1]. For women diagnosed between 2005 and 2009, 
the highest age-standardised survival was seen in Hong Kong (61.5%, 54.8–68.2%), compared with 
only 18.1% (6.3–29.9%) for women in Chile (Los Rios). Age-standardised survival from type II 
epithelial tumours increased over time for most countries worldwide, though there were decreases 
in some countries. In Cuba, for example, survival was 53.4% (45.1–61.7%) for women diagnosed 
during 1995–99, but only 39.2% (29.3–49.1%) during 2005–2009 [SupplementaryTable 1]. 
Between-country variation was widest in Central and South America, where age-standardised 5-
year survival was only 18.1% (6.3–29.9%) in Chile (Los Rios), but 55.0% (44.6–65.5%) in Ecuador 
(Quito). Type II epithelial was the only histological group for which survival estimates could be 
produced for all five African countries, but all of these estimates were not age standardised. 
Survival from germ cell tumours could only be presented for all women diagnosed between 1995 
and 2009, because these tumours are so uncommon. As a result, most survival estimates for germ 
cell tumours were not age standardised. This is because younger women have the highest incidence 
of germ cell tumours and this group is extremely rare in older women. Therefore, only for a few 
countries were enough women available in each age group to allow for age standardisation. 
Considering the age-standardised estimates, the highest was in Australia (76.0%, 57.6–94.5%) and 
the lowest in China (41.5%, 23.6–59.4%). 
Sex cord-stromal tumours are also rare, and survival could only be estimated in 11 countries for all 
three calendar periods. During 2005–2009, net survival was over 90% at 5 years after diagnosis in 
Korea (100.0%, 96.0–100.0%, n = 207 women) and Portugal (94.1%, 83.3–100.0%, n = 64 
women). However, survival varied widely between countries, and the lowest survival was almost 
half that seen in Korea (Japan, 58.9%, 34.2–83.7%, n = 63 women). Over time, survival from sex 
cord-stromal tumours remained either stable, or increased, in most countries [Fig. 2; Supplementary 
Table 1]. 
Survival from other specific non-epithelial tumours was generally around 40% and slightly higher 
than that of type II epithelial tumours. The variation in survival was wide, ranging from only 0.3% 
(0.0–0.8%) in Bulgaria to 60.0% (48.4–71.5%) in Cuba [Fig. 2; Supplementary Table 1]. 
Age-standardised net survival for tumours of non-specific morphology was generally lower than, 
that of tumours with specific morphology, with a few notable exceptions [Supplementary Table 2]. 
Data for 233,659 women were available from 67 registries in 25 countries for analysis of survival 
by stage [Supplementary Fig. 2]. Survival by stage at diagnosis was estimated for all ovarian cancer 
histological groups combined. Only two Central and South American registries provided enough 
information on stage at diagnosis to be included in the analysis. In North America, one Canadian 
registry and 36 US registries provided adequate stage data. In Asia and Europe, only 12 and 13 
registries, respectively, provided adequate stage data for inclusion in survival analyses. No data 
from African registries were available for analysis by stage at diagnosis. 
Overall, 38,033 (16.3%) of these 233,659 women were diagnosed with localised ovarian cancer, 
169,033 (72.3%) with advanced disease and 26,593 (11.4%) with missing stage at diagnosis. The 
overall mean age was 64 years. Women diagnosed with localised ovarian cancer were the youngest 
(mean age 56 years), while women with a missing stage at diagnosis were the oldest (mean age 
68 years). The mean age at diagnoses for women diagnosed with advanced disease was 65 years. 
Overall, 5-year age-standardised net survival for localised ovarian cancer (around 80%) was much 
higher than that for advanced (around 30%) and missing stage at diagnosis (around 30%) [Fig. 3]. 
For women diagnosed with localised ovarian cancer during 2004–2009, survival was much higher 
than for women diagnosed with advanced disease everywhere. In some countries, 5-year age-
standardised survival was over 90% for localised tumours, with the highest survival in Hong Kong 
(95.5%, 89.4–100.0%). The lowest age-standardised survival from localised tumours was seen in 
Mississippi (US) (68.3%, 52.3–84.4%), however, this is still much higher than the highest survival 
for advanced-stage tumours during the same time period. 
For advanced-stage ovarian cancer, survival was generally around 30% [Fig. 3]. Age-standardised 
survival from advanced-stage disease diagnosed during 2004 to 2009 was highest in Tochigi, Japan 
(39.3%, 22.1–56.5%), while the lowest survival was in Manitoba, Canada (15.4%, 9.0–21.7%). The 
between-registry variation in survival for advanced-stage disease was not as wide as that of 
localised disease [Supplementary Table 3]. 
Survival from tumours with missing stage at diagnosis was similar to or lower than that of advanced 
disease in most registries in Central and South America and North America during 2005–2009. For 
a few registries, survival from tumours of missing stage was higher than that for advanced disease. 
In North America, survival from tumours with missing stage at diagnosis was 43.7% (95% CI: 
39.2–48.2) in Texas but only 31.3% (95% CI: 29.6–33.0%) for advanced-stage tumours. In Florida 
and Mississippi, survival for tumours with missing stage was higher than that of advanced-stage 
disease. In contrast to other regions, age-standardised survival from tumours with missing stage was 
higher than for advanced stage disease in all Asian, European and Oceanic registries 
[Supplementary Table 3]. 
4.	Discussion	
There are few international comparisons of survival for the various histological groups of ovarian 
cancer. The results from this large study show the importance of histology in comparisons of 
survival from ovarian cancer between countries. 
The distribution of histological groups may explain some of the wide international variation in 
survival. In Asia, for example, type I epithelial tumours are more common than in other regions, is 
in part due to a higher percentage of clear cell tumours. Because survival for type I epithelial 
tumours is generally higher than that of type II epithelial tumours, we would expect survival for all 
histological groups combined to be higher in Asian countries with this larger proportion of more 
favourable tumours. As shown in the results, survival for all histological groups combined was 
generally higher in Asian countries than other regions. It is therefore important to examine survival 
from ovarian cancer for each histological group separately, at least in international comparisons, 
because survival for all histological groups combined may be influenced by a higher proportion of 
tumours with a more favourable outcome. 
The results also confirm that survival is higher for type I epithelial, germ cell and sex cord-stromal 
tumours than for the more aggressive type II epithelial tumours. Survival from tumours with a non-
specific morphology is also much lower than for tumours in any of these specific histological 
groups. We would expect survival from tumours of non-specific morphology to be even lower than 
that of type II tumours, because most women diagnosed with ovarian cancer for whom a specific 
morphology is not recorded are likely to have been too sick to undergo surgery, which is required 
for pathological examination and morphological classification of the tumour. However, tumours 
recorded as missing morphology or non-specific morphology, may be recorded as such due to lack 
of or incomplete pathological information reported to registries. 
Survival for localised tumours was much higher than for either advanced tumours or tumours with 
missing stage. Early diagnosis of ovarian cancer is thus pathologically important. The result for 
tumours with missing stage is not surprising, because accurate staging can only be achieved if a 
woman has undergone surgery. Women with significantly advanced disease are less likely to have 
surgery and are therefore less likely to be staged appropriately at diagnosis. Furthermore, women 
with higher comorbidity, some of whom will also have advanced-stage disease, may not be healthy 
enough for surgery and may also not have their tumours staged appropriately. 
In some countries, however, survival from tumours with missing stage was higher than that for 
advanced-stage tumours. In these countries, it seems more likely that missing stage at diagnosis 
may be due to lack of reporting stage to registries or incomplete staging at diagnosis. 
Some cancer registries do not routinely collect data on tumour grade, and no information on grade 
was available for this study. Therefore, some serous tumours may have been misclassified, because 
grade is required to classify these tumours appropriately. Only high-grade serous tumours are 
considered as type II epithelial, but we included all serous tumours in our definition of type II 
epithelial, because grade was not available. We feel confident that the effect on survival is small, 
because only a small proportion (5%) of serous tumours are of low grade [14]. 
We have classified all endometrioid tumours as type I epithelial, despite this subtype being 
previously sub-divided into type I and type II epithelial tumours [4]. If grade had been available, 
only low-grade endometrioid tumours would have been classified as type I epithelial while high-
grade endometrioid tumours should have been classified as type II epithelial based on previous 
definitions of type I and type II epithelial tumours [4]. As with low-grade serous tumours, however, 
high-grade endometrioid tumours are rare, so the inclusion of these tumours in the type I epithelial 
group should not greatly affect the survival estimate by histological group [14]. An update in 2016 
to the classification of endometrioid tumours into type I and type II epithelial tumours now 
classifies all endometrioid tumours as type I regardless, of tumour grade [15]. A sensitivity analysis 
was conducted to determine how the survival estimates varied between the two possible 
classifications for endometrioid tumours. Survival for both type I and type II epithelial increased 
when endometrioid tumours were included in each group separately. Because survival from 
endometrioid tumours was generally high when examined separately, we feel confident that 
including these tumours with the less-aggressive type I epithelial subtypes is preferable. 
Tumour stage is not routinely collected by cancer all registries; therefore, the analysis by stage at 
diagnosis could only include data from 25 countries. Additionally, changes in coding of stage at 
diagnosis in the US (72.7% of women included in the analysis) from the Summary Staging Guide 
1977 to SEER Summary Stage 2000 meant that only data from 2001 forward could be included 
from the US. 
The quality and comparability of morphology data between countries may be limited due to 
differences in diagnostic techniques, morphological classification and transfer of data to the cancer 
registry. Almost all tumours submitted by Sweden were type II epithelial, the majority of which 
were unspecific epithelial carcinomas. Given that previous studies show a wider distribution of 
histological subtypes [16], it is unlikely that almost all tumours from Sweden included in our 
analysis would have been true type II epithelial tumours. Additionally, Hong Kong only submitted 
epithelial ovarian cancers when submitting data for the CONCORD-2 study. Therefore, the survival 
comparison is limited to type I and type II epithelial tumours for Hong Kong. 
Our analysis was limited to tumours that had been reported by the registry as microscopically 
verified, though we also included tumours with specific ICD-O-3 morphology codes regardless of 
the reported basis of diagnosis. Microscopic verification requires a tumour biopsy, thus, may not be 
performed if the woman presents with advanced-stage disease and is older or has a high number of 
comorbidities. Additionally, microscopic verification may be difficult in low resource settings, 
where survival may be lower. Therefore, limiting our analysis to microscopically verified tumours 
may overestimate survival. However, given that 92.7% of tumours were microscopically verified, 
the bias would be small. 
Data on treatment are not routinely collected by all cancer registries, and the registries included in 
the CONCORD programme were not asked to submit data on treatment. Therefore, we were unable 
to evaluate the impact of treatment, or lack thereof, on survival estimates for each histological 
group or stage at diagnosis. 
The method of follow-up for obtaining the vital status of registered patients varied between cancer 
registries. Around 60% of registries reported using only passive follow-up, 2% reported only using 
active follow-up and 38% reported using both methods. The majority of patients were followed 
until death or at least five years after diagnosis. The data for this analysis come from the main 
CONCORD-2 data (n = 779,302), in which only 0.6% of women were lost to follow-up and only 
0.6% were censored, or diagnosed from 1995 to 2004 and a vital status of “alive”, but with less than 
five years of follow-up [1]. 
This is the largest international population-based study of survival for ovarian cancer by 
histological group and stage at diagnosis. The large number of women included allowed for 
comparison of survival from epithelial and non-epithelial tumours, which are usually studied 
separately, complicating comparisons of survival between populations or over time. The differences 
in survival between the histological groups emphasise the need to focus future international 
comparisons of ovarian cancer survival on the various subtypes, rather than analysing ovarian 
cancer as a single homogenous group. The results from this analysis also emphasise the need for 
further development of high-quality population-based cancer registries in low-income countries, 
and the continued improvement of the quality and completeness of cancer registry data in all 
countries. 
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